Antihemophilic Factor (Recombinant) Market, Global Outlook and Forecast 2022-2028
Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.
This report contains market size and forecasts of Antihemophilic Factor (Recombinant) in Global, including the following market information:
Global Antihemophilic Factor (Recombinant) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Antihemophilic Factor (Recombinant) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
250IU Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antihemophilic Factor (Recombinant) include Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma and NovoNordisk, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihemophilic Factor (Recombinant) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antihemophilic Factor (Recombinant) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Antihemophilic Factor (Recombinant) Market Segment Percentages, by Type, 2021 (%)
Global Antihemophilic Factor (Recombinant) Market Segment Percentages, by Application, 2021 (%)
Global Antihemophilic Factor (Recombinant) Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Antihemophilic Factor (Recombinant) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Antihemophilic Factor (Recombinant) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
This report contains market size and forecasts of Antihemophilic Factor (Recombinant) in Global, including the following market information:
Global Antihemophilic Factor (Recombinant) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Antihemophilic Factor (Recombinant) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
250IU Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antihemophilic Factor (Recombinant) include Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma and NovoNordisk, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihemophilic Factor (Recombinant) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antihemophilic Factor (Recombinant) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Antihemophilic Factor (Recombinant) Market Segment Percentages, by Type, 2021 (%)
- 250IU
- 500IU
- 1000IU
- 1500IU
- 2000IU
Global Antihemophilic Factor (Recombinant) Market Segment Percentages, by Application, 2021 (%)
- Hospital
- Clinic
Global Antihemophilic Factor (Recombinant) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Antihemophilic Factor (Recombinant) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Antihemophilic Factor (Recombinant) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Takeda
- Bayer
- CSL
- Pfizer
- Biogen
- Octapharma
- NovoNordisk
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Antihemophilic Factor (Recombinant) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antihemophilic Factor (Recombinant) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL ANTIHEMOPHILIC FACTOR (RECOMBINANT) OVERALL MARKET SIZE
2.1 Global Antihemophilic Factor (Recombinant) Market Size: 2021 VS 2028
2.2 Global Antihemophilic Factor (Recombinant) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Antihemophilic Factor (Recombinant) Players in Global Market
3.2 Top Global Antihemophilic Factor (Recombinant) Companies Ranked by Revenue
3.3 Global Antihemophilic Factor (Recombinant) Revenue by Companies
3.4 Top 3 and Top 5 Antihemophilic Factor (Recombinant) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Antihemophilic Factor (Recombinant) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Players in Global Market
3.6.1 List of Global Tier 1 Antihemophilic Factor (Recombinant) Companies
3.6.2 List of Global Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Antihemophilic Factor (Recombinant) Market Size Markets, 2021 & 2028
4.1.2 250IU
4.1.3 500IU
4.1.4 1000IU
4.1.5 1500IU
4.1.6 2000IU
4.2 By Type - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts
4.2.1 By Type - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022
4.2.2 By Type - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028
4.2.3 By Type - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Antihemophilic Factor (Recombinant) Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts
5.2.1 By Application - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022
5.2.2 By Application - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028
5.2.3 By Application - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Antihemophilic Factor (Recombinant) Market Size, 2021 & 2028
6.2 By Region - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts
6.2.1 By Region - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022
6.2.2 By Region - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028
6.2.3 By Region - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.3.2 US Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.3.3 Canada Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.3.4 Mexico Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.4.2 Germany Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.3 France Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.4 U.K. Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.5 Italy Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.6 Russia Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.7 Nordic Countries Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.8 Benelux Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.5.2 China Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.3 Japan Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.4 South Korea Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.5 Southeast Asia Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.6 India Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.6.2 Brazil Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.6.3 Argentina Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.7.2 Turkey Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7.3 Israel Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7.4 Saudi Arabia Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7.5 UAE Antihemophilic Factor (Recombinant) Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Takeda
7.1.1 Takeda Corporate Summary
7.1.2 Takeda Business Overview
7.1.3 Takeda Antihemophilic Factor (Recombinant) Major Product Offerings
7.1.4 Takeda Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.1.5 Takeda Key News
7.2 Bayer
7.2.1 Bayer Corporate Summary
7.2.2 Bayer Business Overview
7.2.3 Bayer Antihemophilic Factor (Recombinant) Major Product Offerings
7.2.4 Bayer Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.2.5 Bayer Key News
7.3 CSL
7.3.1 CSL Corporate Summary
7.3.2 CSL Business Overview
7.3.3 CSL Antihemophilic Factor (Recombinant) Major Product Offerings
7.3.4 CSL Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.3.5 CSL Key News
7.4 Pfizer
7.4.1 Pfizer Corporate Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Antihemophilic Factor (Recombinant) Major Product Offerings
7.4.4 Pfizer Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.4.5 Pfizer Key News
7.5 Biogen
7.5.1 Biogen Corporate Summary
7.5.2 Biogen Business Overview
7.5.3 Biogen Antihemophilic Factor (Recombinant) Major Product Offerings
7.5.4 Biogen Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.5.5 Biogen Key News
7.6 Octapharma
7.6.1 Octapharma Corporate Summary
7.6.2 Octapharma Business Overview
7.6.3 Octapharma Antihemophilic Factor (Recombinant) Major Product Offerings
7.6.4 Octapharma Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.6.5 Octapharma Key News
7.7 NovoNordisk
7.7.1 NovoNordisk Corporate Summary
7.7.2 NovoNordisk Business Overview
7.7.3 NovoNordisk Antihemophilic Factor (Recombinant) Major Product Offerings
7.7.4 NovoNordisk Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.7.5 NovoNordisk Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Antihemophilic Factor (Recombinant) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antihemophilic Factor (Recombinant) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL ANTIHEMOPHILIC FACTOR (RECOMBINANT) OVERALL MARKET SIZE
2.1 Global Antihemophilic Factor (Recombinant) Market Size: 2021 VS 2028
2.2 Global Antihemophilic Factor (Recombinant) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Antihemophilic Factor (Recombinant) Players in Global Market
3.2 Top Global Antihemophilic Factor (Recombinant) Companies Ranked by Revenue
3.3 Global Antihemophilic Factor (Recombinant) Revenue by Companies
3.4 Top 3 and Top 5 Antihemophilic Factor (Recombinant) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Antihemophilic Factor (Recombinant) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Players in Global Market
3.6.1 List of Global Tier 1 Antihemophilic Factor (Recombinant) Companies
3.6.2 List of Global Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Antihemophilic Factor (Recombinant) Market Size Markets, 2021 & 2028
4.1.2 250IU
4.1.3 500IU
4.1.4 1000IU
4.1.5 1500IU
4.1.6 2000IU
4.2 By Type - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts
4.2.1 By Type - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022
4.2.2 By Type - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028
4.2.3 By Type - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Antihemophilic Factor (Recombinant) Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts
5.2.1 By Application - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022
5.2.2 By Application - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028
5.2.3 By Application - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Antihemophilic Factor (Recombinant) Market Size, 2021 & 2028
6.2 By Region - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts
6.2.1 By Region - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022
6.2.2 By Region - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028
6.2.3 By Region - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.3.2 US Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.3.3 Canada Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.3.4 Mexico Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.4.2 Germany Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.3 France Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.4 U.K. Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.5 Italy Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.6 Russia Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.7 Nordic Countries Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.4.8 Benelux Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.5.2 China Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.3 Japan Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.4 South Korea Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.5 Southeast Asia Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.5.6 India Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.6.2 Brazil Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.6.3 Argentina Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, 2017-2028
6.7.2 Turkey Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7.3 Israel Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7.4 Saudi Arabia Antihemophilic Factor (Recombinant) Market Size, 2017-2028
6.7.5 UAE Antihemophilic Factor (Recombinant) Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Takeda
7.1.1 Takeda Corporate Summary
7.1.2 Takeda Business Overview
7.1.3 Takeda Antihemophilic Factor (Recombinant) Major Product Offerings
7.1.4 Takeda Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.1.5 Takeda Key News
7.2 Bayer
7.2.1 Bayer Corporate Summary
7.2.2 Bayer Business Overview
7.2.3 Bayer Antihemophilic Factor (Recombinant) Major Product Offerings
7.2.4 Bayer Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.2.5 Bayer Key News
7.3 CSL
7.3.1 CSL Corporate Summary
7.3.2 CSL Business Overview
7.3.3 CSL Antihemophilic Factor (Recombinant) Major Product Offerings
7.3.4 CSL Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.3.5 CSL Key News
7.4 Pfizer
7.4.1 Pfizer Corporate Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Antihemophilic Factor (Recombinant) Major Product Offerings
7.4.4 Pfizer Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.4.5 Pfizer Key News
7.5 Biogen
7.5.1 Biogen Corporate Summary
7.5.2 Biogen Business Overview
7.5.3 Biogen Antihemophilic Factor (Recombinant) Major Product Offerings
7.5.4 Biogen Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.5.5 Biogen Key News
7.6 Octapharma
7.6.1 Octapharma Corporate Summary
7.6.2 Octapharma Business Overview
7.6.3 Octapharma Antihemophilic Factor (Recombinant) Major Product Offerings
7.6.4 Octapharma Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.6.5 Octapharma Key News
7.7 NovoNordisk
7.7.1 NovoNordisk Corporate Summary
7.7.2 NovoNordisk Business Overview
7.7.3 NovoNordisk Antihemophilic Factor (Recombinant) Major Product Offerings
7.7.4 NovoNordisk Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
7.7.5 NovoNordisk Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Antihemophilic Factor (Recombinant) Market Opportunities & Trends in Global Market
Table 2. Antihemophilic Factor (Recombinant) Market Drivers in Global Market
Table 3. Antihemophilic Factor (Recombinant) Market Restraints in Global Market
Table 4. Key Players of Antihemophilic Factor (Recombinant) in Global Market
Table 5. Top Antihemophilic Factor (Recombinant) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Antihemophilic Factor (Recombinant) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Antihemophilic Factor (Recombinant) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Antihemophilic Factor (Recombinant) Product Type
Table 9. List of Global Tier 1 Antihemophilic Factor (Recombinant) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Antihemophilic Factor (Recombinant) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Antihemophilic Factor (Recombinant) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 30. Takeda Corporate Summary
Table 31. Takeda Antihemophilic Factor (Recombinant) Product Offerings
Table 32. Takeda Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 33. Bayer Corporate Summary
Table 34. Bayer Antihemophilic Factor (Recombinant) Product Offerings
Table 35. Bayer Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 36. CSL Corporate Summary
Table 37. CSL Antihemophilic Factor (Recombinant) Product Offerings
Table 38. CSL Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Antihemophilic Factor (Recombinant) Product Offerings
Table 41. Pfizer Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 42. Biogen Corporate Summary
Table 43. Biogen Antihemophilic Factor (Recombinant) Product Offerings
Table 44. Biogen Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 45. Octapharma Corporate Summary
Table 46. Octapharma Antihemophilic Factor (Recombinant) Product Offerings
Table 47. Octapharma Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 48. NovoNordisk Corporate Summary
Table 49. NovoNordisk Antihemophilic Factor (Recombinant) Product Offerings
Table 50. NovoNordisk Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 1. Antihemophilic Factor (Recombinant) Market Opportunities & Trends in Global Market
Table 2. Antihemophilic Factor (Recombinant) Market Drivers in Global Market
Table 3. Antihemophilic Factor (Recombinant) Market Restraints in Global Market
Table 4. Key Players of Antihemophilic Factor (Recombinant) in Global Market
Table 5. Top Antihemophilic Factor (Recombinant) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Antihemophilic Factor (Recombinant) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Antihemophilic Factor (Recombinant) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Antihemophilic Factor (Recombinant) Product Type
Table 9. List of Global Tier 1 Antihemophilic Factor (Recombinant) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Antihemophilic Factor (Recombinant) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Antihemophilic Factor (Recombinant) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Antihemophilic Factor (Recombinant) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2023-2028
Table 30. Takeda Corporate Summary
Table 31. Takeda Antihemophilic Factor (Recombinant) Product Offerings
Table 32. Takeda Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 33. Bayer Corporate Summary
Table 34. Bayer Antihemophilic Factor (Recombinant) Product Offerings
Table 35. Bayer Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 36. CSL Corporate Summary
Table 37. CSL Antihemophilic Factor (Recombinant) Product Offerings
Table 38. CSL Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Antihemophilic Factor (Recombinant) Product Offerings
Table 41. Pfizer Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 42. Biogen Corporate Summary
Table 43. Biogen Antihemophilic Factor (Recombinant) Product Offerings
Table 44. Biogen Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 45. Octapharma Corporate Summary
Table 46. Octapharma Antihemophilic Factor (Recombinant) Product Offerings
Table 47. Octapharma Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
Table 48. NovoNordisk Corporate Summary
Table 49. NovoNordisk Antihemophilic Factor (Recombinant) Product Offerings
Table 50. NovoNordisk Antihemophilic Factor (Recombinant) Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Antihemophilic Factor (Recombinant) Segment by Type in 2021
Figure 2. Antihemophilic Factor (Recombinant) Segment by Application in 2021
Figure 3. Global Antihemophilic Factor (Recombinant) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Antihemophilic Factor (Recombinant) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Antihemophilic Factor (Recombinant) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Antihemophilic Factor (Recombinant) Revenue in 2021
Figure 8. By Type - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 12. US Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 16. Germany Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 17. France Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 24. China Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 28. India Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 30. Brazil Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 33. Turkey Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 37. Takeda Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bayer Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. CSL Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Biogen Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Octapharma Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. NovoNordisk Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Antihemophilic Factor (Recombinant) Segment by Type in 2021
Figure 2. Antihemophilic Factor (Recombinant) Segment by Application in 2021
Figure 3. Global Antihemophilic Factor (Recombinant) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Antihemophilic Factor (Recombinant) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Antihemophilic Factor (Recombinant) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Antihemophilic Factor (Recombinant) Revenue in 2021
Figure 8. By Type - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 12. US Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 16. Germany Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 17. France Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 24. China Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 28. India Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 30. Brazil Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
Figure 33. Turkey Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Antihemophilic Factor (Recombinant) Revenue, (US$, Mn), 2017-2028
Figure 37. Takeda Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bayer Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. CSL Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Biogen Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Octapharma Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. NovoNordisk Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
